Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estude para aprender sobre a segurança do Fazirsiran e se ele pode ajudar pessoas com doença hepática alfa-1 antitripsina com cicatrizes hepáticas leves (fibrose)

6 de novembro de 2026 atualizado por: Takeda

Um estudo randomizado, duplo-cego, controlado por placebo, de fase 3 para avaliar a segurança e eficácia de Fazirsiran no tratamento de doença hepática associada à deficiência de alfa-1 antitripsina com fibrose METAVIR estágio F1

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver.

People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.

After their last clinic visits, participants will have two choices:

  1. They can complete this study and return to the clinic 3 and 6 months later so the study doctors can check for side effects; OR
  2. If they meet the rules, they can join another study (called extension or continuation study), in which they will receive fazirsiran every 3 months and will continue to have health checks.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

50

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Aachen, Alemanha, 52074
        • Recrutamento
        • Universitätsklinikum der RWTH Aachen
        • Investigador principal:
          • Pavel Strnad
        • Contato:
      • Berlin, Alemanha, 13353
        • Recrutamento
        • Charité - Campus Virchow-Klinikum
        • Contato:
        • Investigador principal:
          • Frank Tacke
      • Hanover, Alemanha, 30625
        • Recrutamento
        • Hannover Medical School
        • Investigador principal:
          • Heiner Wedemeyer
        • Contato:
          • Site Contact
          • Número de telefone: +495115322730
      • Tübingen, Alemanha, 72076
        • Recrutamento
        • Universitätsklinikum Tübingen
        • Investigador principal:
          • Christoph Berg
        • Contato:
          • Site Contact
          • Número de telefone: +4970712977661
      • Antwerp, Bélgica, 2650
        • Recrutamento
        • UZ Antwerpen
        • Investigador principal:
          • Sven Francque
        • Contato:
      • Leuven, Bélgica, 3000
        • Recrutamento
        • UZ Leuven
        • Investigador principal:
          • Jef Verbeek
        • Contato:
    • Ontario
      • Toronto, Ontario, Canadá, M5T 3A9
        • Recrutamento
        • Inspiration Research Limited
        • Investigador principal:
          • Kenneth Chapman
        • Contato:
          • Site Contact
          • Número de telefone: (416) 944-9602
      • Seville, Espanha, 41018
        • Recrutamento
        • Hospital Universitario Virgen del Rocio - PPDS
        • Contato:
        • Investigador principal:
          • Manuel Romero Gómez
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85013-4224
        • Recrutamento
        • St Joseph's Hospital and Medical Center
        • Investigador principal:
          • Justin Reynolds
        • Contato:
          • Site Contact
          • Número de telefone: 602-274-7195
      • Phoenix, Arizona, Estados Unidos, 85054-4502
        • Recrutamento
        • Mayo Clinic - PPDS
        • Investigador principal:
          • Hugo Vargas
        • Contato:
      • Tucson, Arizona, Estados Unidos, 85724-0001
        • Recrutamento
        • University of Arizona Thomas D. Boyer Liver Institute
        • Contato:
        • Investigador principal:
          • Geoffrey Block
    • California
      • La Jolla, California, Estados Unidos, 92037-1337
        • Recrutamento
        • University of California San Diego
        • Investigador principal:
          • Rohit Loomba
        • Contato:
      • Los Angeles, California, Estados Unidos, 90095-3075
        • Recrutamento
        • UCLA Pulmonary and Critical Care
        • Investigador principal:
          • Igor Barjaktarevic
        • Contato:
          • Site Contact
          • Número de telefone: 310-825-8061
      • San Francisco, California, Estados Unidos, 94143-2203
        • Recrutamento
        • University of California Benioff Children's Hospital
        • Investigador principal:
          • Philip Rosenthal
        • Contato:
    • Colorado
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Recrutamento
        • Peak Gastroenterology Associates
        • Investigador principal:
          • Bhaktasharan Patel
        • Contato:
          • Site Contact
          • Número de telefone: 719-636-1201
    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • Recrutamento
        • Schiff Center for Liver Diseases/University of Miami
        • Investigador principal:
          • Eugene Schiff
        • Contato:
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202-2266
        • Recrutamento
        • Indiana University School of Medicine-Indianapolis
        • Investigador principal:
          • Raj Vuppalanchi
        • Contato:
          • Site Contact
          • Número de telefone: 317-278-4607
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242-1009
        • Recrutamento
        • University Of Iowa Hospitals And Clinics
        • Investigador principal:
          • Tomohiro Tanaka
        • Contato:
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02118-2335
        • Recrutamento
        • Boston Medical Center
        • Investigador principal:
          • Arpan Mohanty
        • Contato:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan Hospital - 1500 E Medical Center Dr
        • Investigador principal:
          • Robert Fontana
        • Contato:
          • Site Contact
          • Número de telefone: 734-232-3741
      • Novi, Michigan, Estados Unidos, 48377-3600
        • Recrutamento
        • Henry Ford Health System
        • Investigador principal:
          • Stuart Gordon
        • Contato:
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic PPDS
        • Investigador principal:
          • Harmeet Malhi
        • Contato:
          • Site Contact
          • Número de telefone: 507-284-0141
    • New York
      • New York, New York, Estados Unidos, 10016-6402
        • Recrutamento
        • NYU Langone Medical Center
        • Investigador principal:
          • Viviana Figueroa Diaz
        • Contato:
      • New York, New York, Estados Unidos, 10032-3722
        • Recrutamento
        • Columbia University Irving Medical Center
        • Investigador principal:
          • Monica Goldklang
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106-1716
        • Recrutamento
        • University Hospitals Cleveland Medical Center
        • Investigador principal:
          • Seth Sclair
        • Contato:
          • Site Contact
          • Número de telefone: 216-983-0879
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033-2360
        • Recrutamento
        • Penn State Health Milton S. Hershey Medical Center
        • Investigador principal:
          • Timothy Craig
        • Contato:
    • Texas
      • San Antonio, Texas, Estados Unidos, 78215
        • Recrutamento
        • Texas Liver Institute American Research Corporation
        • Investigador principal:
          • Eric Lawitz
        • Contato:
    • Virginia
      • Newport, Virginia, Estados Unidos, 23602-4414
        • Recrutamento
        • Bon Secours St. Mary's Hospital
        • Contato:
        • Investigador principal:
          • Mitchell Schiffman
      • Lyon, França, 69317
        • Recrutamento
        • Hôpital de La Croix Rousse
        • Contato:
        • Investigador principal:
          • Teresa Antonini
      • Rennes, França, 35000
        • Recrutamento
        • Hopital PONTCHAILLOU CHU de Rennes
        • Contato:
        • Investigador principal:
          • Edouard Bardou-Jacquet
      • Val-de-Marne, França, 94800
        • Recrutamento
        • Hôpital Paul Brousse
        • Contato:
        • Investigador principal:
          • Audrey Coilly
      • Pavia, Itália, 27100
        • Recrutamento
        • Fondazione IRCCS Policlinico San Matteo
        • Investigador principal:
          • Angelo Corsico
        • Contato:
          • Site Contact
          • Número de telefone: +390382503777
      • Mysłowice, Polônia, 41-400
        • Retirado
        • ID Clinic Arkadiusz Pisula
      • Braga, Portugal, 4710-243
        • Recrutamento
        • CCA Hospital Braga
        • Investigador principal:
          • Carla Rolanda
      • Funchal, Portugal, 9000-168
        • Recrutamento
        • Hospital Dr. Nélio Mendonça
        • Investigador principal:
          • Vitor Pereira
        • Contato:
          • Site Contact
          • Número de telefone: (351) 291-7056 x00
      • Porto, Portugal, 4099-001
        • Recrutamento
        • Centro Hospitalar de Universitário de Santo António E.P.E
        • Contato:
          • Site Contact
          • Número de telefone: +351918000000
        • Investigador principal:
          • Luís Maia
      • London, Reino Unido, SE5 9RS
        • Recrutamento
        • King's College Hospital
        • Investigador principal:
          • Aftab Ala
        • Contato:
          • Site Contact
          • Número de telefone: +442032993506
      • Huddinge, Suécia, 14186
        • Recrutamento
        • Karolinska Universitetssjukhuset Huddinge
        • Contato:
          • Site Contact
          • Número de telefone: +46858580000
        • Investigador principal:
          • Staffan Wahlin
      • Bern, Suíça, 3010
        • Recrutamento
        • Universitätsspital Bern
        • Investigador principal:
          • Guido Stirnimann
        • Contato:
          • Site Contact
          • Número de telefone: +41442663568
      • Graz, Áustria, 8036
        • Recrutamento
        • LKH-Universitätsklinikum Graz
        • Contato:
        • Investigador principal:
          • Martin Wagner
      • Klagenfurt, Áustria, 9020
        • Recrutamento
        • KABEG - Klinikum Klagenfurt Am Wörthersee
        • Investigador principal:
          • Markus Peck-Radosavljevic

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • In the opinion of the investigator, the participant is capable of understanding and fully complying with the protocol requirements and adhering to the protocol schedule.
  • The participant is able to read, understand, and complete the study questionnaires electronically per the investigator's judgment.
  • The participant signs and dates a written Informed Consent Form (ICF). Any required privacy authorization should also be signed before the initiation of any study procedures.
  • The participant, of any sex, is aged 18 to 75 years, inclusive.
  • The participant must have a diagnosis of the protease inhibitor Z mutation (PiZZ) genotype AATD. A diagnosis of PiZZ from source-verifiable medical records is permitted. Otherwise, participants must undergo PiZZ confirmatory testing (genotyping for PiS and PiZ alleles) at screening. PiMZ or PiSZ genotypes are not permitted.
  • The participant's liver biopsy core samples collected as per protocol requirements.
  • The participant has evidence of METAVIR stage F1 liver fibrosis, evaluated by a centrally read baseline liver biopsy during the screening period; or confirmed as meeting all the entry criteria by central reading from a previous biopsy conducted within 1 year before the estimated enrollment date using an adequate liver biopsy and slides as defined in the study laboratory manual.
  • The participant has a pulmonary status that meets the protocol requirements.
  • It must be confirmed that the participant does not have hepatocellular carcinoma (HCC).
  • Any participant who is taking statins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, or beta-1 selective adrenergic receptor inhibitors must have been receiving a stable dose of these medications for at least 8 weeks before randomization. All attempts are to be made for the participant to continue the same dose of the medication for the duration of study participation.
  • An adult participant must have a body mass index (BMI) greater than or equal to (>=) 18 kilogram per meter square (kg/m^2).
  • The participant has a 12-lead electrocardiogram at screening that, in the opinion of the investigator, has no abnormalities that could compromise the participant's safety in this study.
  • The participant is a nonsmoker.
  • If the participant was being treated with any respiratory medications including inhaled bronchodilators, inhaled anticholinergics, inhaled corticosteroids, or low-dose systemic corticosteroids (prednisone less than or equal to [<=10] milligrams per day [mg/d] or its equivalent), the doses of the participant's medications must have remained unchanged for >=4 weeks before screening.
  • The participant must have suitable venous access for blood sampling.
  • A person of childbearing potential (POCBP) must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day 1 before dosing.
  • The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study and for 6 months after the last dose of study medication. The participant must not donate sperm for at least 6 months after the last dose of study medication.

Exclusion criteria:

  • The participant has evidence of >= F2 fibrosis based on liver biopsy during the screening period.
  • The participant has a history of liver decompensating events.
  • The participant has a history of varices based on a previous esophagogastroduodenoscopy.
  • The participant has portal vein thrombosis.
  • The participant has undergone a prior trans-jugular portosystemic shunt procedure.
  • The participant has evidence of other forms of chronic liver diseases.
  • The participant has a history of malignancy within the last 5 years, except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer. Participants with curatively treated malignancies who have no evidence of metastatic disease and disease-free interval greater than (>) 1 year may be enrolled. Individual cases may be discussed with the medical monitor for guidance.
  • The participant has an abnormal finding of clinical relevance at the screening evaluation and before administration of the first dose of study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results.
  • The participant has any laboratory abnormalities at screening and before the first dose of the study drug that meet protocol parameters.
  • The participant is expected to have severe and unavoidable high-level exposure to inhaled pulmonary toxins during the study such as may occur with occupational exposure to mineral dusts or metals.
  • The participant has a recent lower respiratory tract infection, such as pneumonia, within the last 6 months prior to screening, unless, in the opinion of the investigator, the participant has achieved clinical recovery with pulmonary function returned to baseline. Individual cases may be discussed with the medical monitor for guidance.
  • The participant has a history of frequent pulmonary exacerbations (>=2 moderate or severe exacerbations within 52 weeks before screening).
  • The participant is experiencing a pulmonary exacerbation at the time of screening (participant may be rescreened after the clinical resolution of an exacerbation).
  • The participant is receiving long-term, around-the-clock oxygen supplementation or supplemental oxygen with continuous positive airway pressure (CPAP) or bilevel positive airway pressure for acute respiratory failure. The following conditions are allowable for the participant to enter screening: short-term use of oxygen supplementation (example, for the management of acute chronic obstructive pulmonary disease [COPD] exacerbation) or CPAP for obstructive sleep apnea.
  • The participant has human immunodeficiency virus (HIV) infection as shown by the presence of anti-HIV antibody (seropositive).
  • The participant is seropositive for hepatitis B virus (HBV surface antigen positive and/or HBV core antibody positive without HBV surface antibody at screening) or hepatitis C virus (HCV) (detectable HCV Ribonucleic Acid [RNA] at screening). Cured HCV (positive antibody test without detectable HCV RNA for at least 6 months after treatment) is acceptable.
  • The participant has unstable, poorly controlled, or severe hypertension. Participants may be rescreened once their blood pressure (BP) is successfully controlled.
  • The participant has a history of ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if they participate in the study, in the opinion of the investigator. Examples of significant ECG abnormalities include: torsades de pointes, ventricular rhythm disturbances (example, ventricular tachycardia), heart block (excluding first-degree block, being PR interval prolongation only), congenital long QT syndrome or new ST-segment elevation or depression or a new Q wave on ECG.
  • The participant has symptomatic heart failure (per New York Heart Association guidelines), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction less than [<] 20 percent [%]), transient ischemic attack, or cerebrovascular accident within 6 months before screening.
  • The participant has a history of major surgery within 12 weeks of screening (or longer, at the discretion of the investigator).
  • The participant has a history of more than moderate alcohol consumption within 12 months before the screening visit.
  • The participant has a history of drug abuse (such as cocaine, phencyclidine) within 1 year before the screening visit or has a positive urine drug screen at screening.
  • The participant has previously been treated with fazirsiran or any other RNA interference (RNAi) for alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).
  • The participant has a history of hypersensitivity or allergies with any associated excipients of fazirsiran.
  • The participant has received an investigational agent or device within 30 days, or 5 half-lives, whichever is longer, before the dosing of study medication or is currently participating in an investigational study involving a therapeutic intervention.
  • The participant has donated >=500 milliliter (mL) of blood within 1 month of the administration of study treatment.
  • The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk. The participant has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurologic, psychiatric, gastrointestinal (GI), systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
  • The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 6 months before screening, or is taking chronic anticoagulants.
  • This participant is unable to return for all scheduled study visits.
  • The participant has symptomatic confirmed coronavirus disease 2019 (COVID-19) that, in the opinion of the investigator, does not resolve during screening; however, enrollment may be temporarily delayed at the discretion of the investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation. Individual cases may be discussed with the medical monitor for guidance.
  • The participant is a study site employee involved in the conduct of this study, an immediate family member (example, spouse, parent, child, sibling), is in a dependent relationship with study site employee who is involved in the conduct of this study or may consent under duress.
  • The participant takes or is required to take excluded medications.
  • The participant is pregnant or breastfeeding or intending to become pregnant before participating in this study, during the study, or within 6 months after last dose of the study drug; or the participant is intending to donate ova during such time period.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Fazirsiran 200 mg

Participants will receive fazirsiran 200 milligrams (mg), injection, subcutaneously on Day 1, at Week 4 and then every 12 weeks (Q12W) for up to Week 100.

Fazirsiran will be injected subcutaneously.

Outros nomes:
  • TAK-999
  • ARO-AAT
  • ADS-001
Comparador de Placebo: Placebo

Participants will receive fazirsiran matching placebo injection, subcutaneously on Day 1, at Week 4 and Q12W for up to Week 100.

Fazirsiran matching placebo.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Prazo: From start of study drug administration up to end of study (EOS) (Week 124)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported.

From start of study drug administration up to end of study (EOS) (Week 124)
Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function Parameters
Prazo: From start of study drug administration up to EOS (Week 124)

Standard pulmonary function parameters will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)
Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung Densitometry
Prazo: Baseline up to Week 100

Change from baseline in whole lung 15th percentile density as measured by CT lung densitometry will be assessed.

Baseline up to Week 100
Number of Participants With Clinically Significant Changes in Vital Signs
Prazo: From start of study drug administration up to EOS (Week 124)

Vital signs include body temperature, respiratory rate, blood pressure (systolic and diastolic), pulse (beats per minute) and pulse oximetry. Clinical significance of vital signs will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)
Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Prazo: From start of study drug administration up to EOS (Week 124)

12-lead ECG will be evaluated. Any clinically significant change in ECG assessments will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Prazo: From start of study drug administration up to EOS (Week 124)

Laboratory parameters assessments include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion.

From start of study drug administration up to EOS (Week 124)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change From Baseline in Serum Z-AAT Protein Over Time to Week 106
Prazo: Baseline up to Week 106

Change From Baseline in Serum Z-AAT Protein will be assessed.

Baseline up to Week 106
Percent Change From Baseline in Intrahepatic Liver Z-AAT Protein at Week 106
Prazo: Baseline up to Week 106

Percent change from baseline in intrahepatic liver Z-AAT protein will be assessed.

Baseline up to Week 106
Change From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 106
Prazo: Baseline up to Week 106

Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy will be assessed.

Baseline up to Week 106
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by PAS+D Staining at Week 106
Prazo: Baseline up to Week 106

Number of participants with no change or decrease from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining will be reported.

Baseline up to Week 106
Change From Baseline in Intrahepatic Portal Inflammation Score in Liver Biopsy at Week 106
Prazo: Baseline up to Week 106

Change in portal inflammation score in liver biopsy is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation.

Baseline up to Week 106
Number of Participants with No Change or Decrease From Baseline in Intrahepatic Portal Inflammation Score at Week 106
Prazo: Baseline up to Week 106

No Change or decrease in portal inflammation score is based on pathology slide reads. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation. Number of Participants with no change or decrease from baseline in intrahepatic portal inflammation score will be reported.

Baseline up to Week 106
Number of Participants With No Change or Decrease From Baseline in Histologic Fibrosis Score (Meta-analysis of Histological Data in Viral Hepatitis [METAVIR] Staging) at Week 106
Prazo: Baseline up to Week 106

No change or decrease in histologic fibrosis (METAVIR staging) will be assessed using a fibrosis score of F0-F4, where higher scores mean a worse result. Number of participants with no change or decrease from baseline in histologic fibrosis score (by [METAVIR] staging) at Week 106 will be reported.

Baseline up to Week 106
Change From Baseline in Vibration-Controlled Transient Elastography (VCTE)-Derived Liver Stiffness
Prazo: Baseline up to Week 106

Change from baseline in VCTE-derived liver stiffness will be assessed.

Baseline up to Week 106
Change From Baseline in Markers of Liver Injury
Prazo: Baseline up to Week 106

Change from baseline in marker (alanine aminotransferase [ALT], aspartate aminotransferase [AST], glutamyl transferase [GGT]) of liver injury will be assessed.

Baseline up to Week 106

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Study Director, Takeda

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de março de 2024

Conclusão Primária (Estimado)

26 de agosto de 2028

Conclusão do estudo (Estimado)

26 de agosto de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

1 de dezembro de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de dezembro de 2023

Primeira postagem (Real)

11 de dezembro de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • TAK-999-3002
  • 2023-504198-19-00 (Ctis: EU CTIS)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Critérios de acesso de compartilhamento IPD

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .